303 related articles for article (PubMed ID: 29519793)
1. MRI Features Can Predict 1p/19q Status in Intracranial Gliomas.
Lasocki A; Gaillard F; Gorelik A; Gonzales M
AJNR Am J Neuroradiol; 2018 Apr; 39(4):687-692. PubMed ID: 29519793
[TBL] [Abstract][Full Text] [Related]
2. The T2-FLAIR-mismatch sign as an imaging biomarker for IDH and 1p/19q status in diffuse low-grade gliomas: a systematic review with a Bayesian approach to evaluation of diagnostic test performance.
Goyal A; Yolcu YU; Goyal A; Kerezoudis P; Brown DA; Graffeo CS; Goncalves S; Burns TC; Parney IF
Neurosurg Focus; 2019 Dec; 47(6):E13. PubMed ID: 31786548
[TBL] [Abstract][Full Text] [Related]
3. MRI Scoring Systems for Predicting Isocitrate Dehydrogenase Mutation and Chromosome 1p/19q Codeletion in Adult-type Diffuse Glioma Lacking Contrast Enhancement.
Kang KM; Song J; Choi Y; Park C; Park JE; Kim HS; Park SH; Park CK; Choi SH
Radiology; 2024 May; 311(2):e233120. PubMed ID: 38713025
[TBL] [Abstract][Full Text] [Related]
4. Radiogenomics Provides Insights into Gliomas Demonstrating Single-Arm 1p or 19q Deletion.
Lasocki A; Buckland ME; Molinaro T; Xie J; Gaillard F
AJNR Am J Neuroradiol; 2023 Nov; 44(11):1270-1274. PubMed ID: 37884300
[TBL] [Abstract][Full Text] [Related]
5. MRI and CT Identify Isocitrate Dehydrogenase
Patel SH; Batchala PP; Mrachek EKS; Lopes MS; Schiff D; Fadul CE; Patrie JT; Jain R; Druzgal TJ; Williams ES
Radiology; 2020 Jan; 294(1):160-167. PubMed ID: 31714193
[TBL] [Abstract][Full Text] [Related]
6. Neuroimaging-Based Classification Algorithm for Predicting 1p/19q-Codeletion Status in
Batchala PP; Muttikkal TJE; Donahue JH; Patrie JT; Schiff D; Fadul CE; Mrachek EK; Lopes MB; Jain R; Patel SH
AJNR Am J Neuroradiol; 2019 Mar; 40(3):426-432. PubMed ID: 30705071
[TBL] [Abstract][Full Text] [Related]
7. Prediction of
Park YW; Han K; Ahn SS; Bae S; Choi YS; Chang JH; Kim SH; Kang SG; Lee SK
AJNR Am J Neuroradiol; 2018 Jan; 39(1):37-42. PubMed ID: 29122763
[TBL] [Abstract][Full Text] [Related]
8. Whole-Tumor Histogram and Texture Analyses of DTI for Evaluation of
Park YW; Han K; Ahn SS; Choi YS; Chang JH; Kim SH; Kang SG; Kim EH; Lee SK
AJNR Am J Neuroradiol; 2018 Apr; 39(4):693-698. PubMed ID: 29519794
[TBL] [Abstract][Full Text] [Related]
9. Predicting 1p/19q codeletion status using diffusion-, susceptibility-, perfusion-weighted, and conventional MRI in IDH-mutant lower-grade gliomas.
Yang X; Lin Y; Xing Z; She D; Su Y; Cao D
Acta Radiol; 2021 Dec; 62(12):1657-1665. PubMed ID: 33222488
[TBL] [Abstract][Full Text] [Related]
10. Predicting the 1p/19q Codeletion Status of Presumed Low-Grade Glioma with an Externally Validated Machine Learning Algorithm.
van der Voort SR; Incekara F; Wijnenga MMJ; Kapas G; Gardeniers M; Schouten JW; Starmans MPA; Nandoe Tewarie R; Lycklama GJ; French PJ; Dubbink HJ; van den Bent MJ; Vincent AJPE; Niessen WJ; Klein S; Smits M
Clin Cancer Res; 2019 Dec; 25(24):7455-7462. PubMed ID: 31548344
[TBL] [Abstract][Full Text] [Related]
11. Prediction of oligodendroglial histology and LOH 1p/19q using dynamic [(18)F]FET-PET imaging in intracranial WHO grade II and III gliomas.
Jansen NL; Schwartz C; Graute V; Eigenbrod S; Lutz J; Egensperger R; Pöpperl G; Kretzschmar HA; Cumming P; Bartenstein P; Tonn JC; Kreth FW; la Fougère C; Thon N
Neuro Oncol; 2012 Dec; 14(12):1473-80. PubMed ID: 23090986
[TBL] [Abstract][Full Text] [Related]
12. T2-FLAIR Mismatch, an Imaging Biomarker for IDH and 1p/19q Status in Lower-grade Gliomas: A TCGA/TCIA Project.
Patel SH; Poisson LM; Brat DJ; Zhou Y; Cooper L; Snuderl M; Thomas C; Franceschi AM; Griffith B; Flanders AE; Golfinos JG; Chi AS; Jain R
Clin Cancer Res; 2017 Oct; 23(20):6078-6085. PubMed ID: 28751449
[No Abstract] [Full Text] [Related]
13. Advanced imaging parameters improve the prediction of diffuse lower-grade gliomas subtype, IDH mutant with no 1p19q codeletion: added value to the T2/FLAIR mismatch sign.
Lee MK; Park JE; Jo Y; Park SY; Kim SJ; Kim HS
Eur Radiol; 2020 Feb; 30(2):844-854. PubMed ID: 31446467
[TBL] [Abstract][Full Text] [Related]
14. Conventional Magnetic Resonance Features for Predicting 1p19q Codeletion Status of World Health Organization Grade II and III Diffuse Gliomas.
Peng X; Yishuang C; Kaizhou Z; Xiao L; Ma C
J Comput Assist Tomogr; 2019; 43(2):269-276. PubMed ID: 30371623
[TBL] [Abstract][Full Text] [Related]
15. Cystathionine as a marker for 1p/19q codeleted gliomas by in vivo magnetic resonance spectroscopy.
Branzoli F; Pontoizeau C; Tchara L; Di Stefano AL; Kamoun A; Deelchand DK; Valabrègue R; Lehéricy S; Sanson M; Ottolenghi C; Marjańska M
Neuro Oncol; 2019 Jun; 21(6):765-774. PubMed ID: 30726924
[TBL] [Abstract][Full Text] [Related]
16. MR textural analysis on T
Rui W; Ren Y; Wang Y; Gao X; Xu X; Yao Z
J Magn Reson Imaging; 2018 Jul; 48(1):74-83. PubMed ID: 29140606
[TBL] [Abstract][Full Text] [Related]
17. Genetically Defined Oligodendroglioma Is Characterized by Indistinct Tumor Borders at MRI.
Johnson DR; Diehn FE; Giannini C; Jenkins RB; Jenkins SM; Parney IF; Kaufmann TJ
AJNR Am J Neuroradiol; 2017 Apr; 38(4):678-684. PubMed ID: 28126746
[TBL] [Abstract][Full Text] [Related]
18. Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion.
Kawaguchi T; Sonoda Y; Shibahara I; Saito R; Kanamori M; Kumabe T; Tominaga T
J Neurooncol; 2016 Sep; 129(3):505-514. PubMed ID: 27401154
[TBL] [Abstract][Full Text] [Related]
19. Imaging correlates for the 2016 update on WHO classification of grade II/III gliomas: implications for IDH, 1p/19q and ATRX status.
Delfanti RL; Piccioni DE; Handwerker J; Bahrami N; Krishnan A; Karunamuni R; Hattangadi-Gluth JA; Seibert TM; Srikant A; Jones KA; Snyder VS; Dale AM; White NS; McDonald CR; Farid N
J Neurooncol; 2017 Dec; 135(3):601-609. PubMed ID: 28871469
[TBL] [Abstract][Full Text] [Related]
20. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.
Barbashina V; Salazar P; Holland EC; Rosenblum MK; Ladanyi M
Clin Cancer Res; 2005 Feb; 11(3):1119-28. PubMed ID: 15709179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
